Skip to main content
Clinical Trials/NCT03215628
NCT03215628
Completed
N/A

Quantifizierung Der Hirnperfusion Während Kinderherzchirurgischer Operationen Durch Transkraniellen Kontrastmittelverstärkten Ultraschall

University of Erlangen-Nürnberg Medical School1 site in 1 country12 target enrollmentJuly 4, 2017

Overview

Phase
N/A
Intervention
Not specified
Conditions
Heart Defects, Congenital
Sponsor
University of Erlangen-Nürnberg Medical School
Enrollment
12
Locations
1
Primary Endpoint
Time-To-Peak (TTP)
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Transcranial contrast-enhanced ultrasound for evaluation of cerebral blood flow during pediatric cardiac surgery. This study is aimed as a feasibility study prior to conducting a lager prospective clinical trial including neurologic and developmental outcome measures.

Detailed Description

The cerebral perfusion of infants with congenital heart defects is a critical determinant during cardiac surgery. The majority of these interventions is performed during deep or moderate hypothermia (25-32°C) with reduced blood flow of the heart-lung-machine (HLM). Assuming a symmetrical anatomy of the cerebral arteries (C. Willisii) a single vessel (T. brachiocephalicus) is then supplying the cerebral blood flow. Using contrast-enhanced ultrasound the cerebral blood flow will be assessed during cardiac surgery interventions.

Registry
clinicaltrials.gov
Start Date
July 4, 2017
End Date
August 30, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
University of Erlangen-Nürnberg Medical School
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Neonates and infants ≤ 4 month (open fontanelle)
  • Proper ultrasound conditions/window
  • Appropriate general and neurologic state of health
  • Written consent of both parents/guardians
  • Availability of trained sonographer (medical doctor)

Exclusion Criteria

  • Absence of trained sonographer (medical doctor)
  • Intolerance against SonoVue® (bzw. sulphur hexafluoride)
  • Missing signed consent
  • Reduced or inappropriate general and neurologic state of health
  • Preexisting cerebral injury

Outcomes

Primary Outcomes

Time-To-Peak (TTP)

Time Frame: Intraoperative (Directly after start of surgical intervention (T1) vs. Directly before end of intervention (T5))

Relative/percentage difference of cerebral perfusion by TCEUS-based quantification using VueBox(R) software

Mean-Transit-Time (MTT)

Time Frame: Intraoperative (Directly after start of surgical intervention (T1) vs. Directly before end of intervention (T5))

Relative/percentage difference of cerebral perfusion by TCEUS-based quantification using VueBox(R) software

Maximum Intensity (MI)

Time Frame: Intraoperative (Directly after start of surgical intervention (T1) vs. Directly before end of intervention (T5))

Relative/percentage difference of cerebral perfusion by TCEUS-based quantification using VueBox(R) software

Relative Blood Volume (RBV)

Time Frame: Intraoperative (Directly after start of surgical intervention (T1) vs. Directly before end of intervention (T5))

Relative/percentage difference of cerebral perfusion by TCEUS-based quantification using VueBox(R) software

Relative Blood Flow (RBF)

Time Frame: Intraoperative (Directly after start of surgical intervention (T1) vs. Directly before end of intervention (T5))

Relative/percentage difference of cerebral perfusion by TCEUS-based quantification using VueBox(R) software

Secondary Outcomes

  • Time-To-Peak (TTP)(Directly after start of surgical intervention (T1) vs. Directly after low flow of HLM at 25-28°C/hypothermia (T4))
  • Mean-Transit-Time (MTT)(Directly after start of surgical intervention (T1) vs. Directly after low flow of HLM at 25-28°C/hypothermia (T4))
  • Maximum Intensity (MI)(Directly after start of surgical intervention (T1) vs. Directly after low flow of HLM at 25-28°C/hypothermia (T4))
  • Relative Blood Volume (RBV)(Directly after start of surgical intervention (T1) vs. Directly after low flow of HLM at 25-28°C/hypothermia (T4))
  • Relative Blood Flow (RBF)(Directly after start of surgical intervention (T1) vs. Directly after low flow of HLM at 25-28°C/hypothermia (T4))

Study Sites (1)

Loading locations...

Similar Trials